TRKA yields 1503.76% · ABBV yields 3.06%● Live data
📍 TRKA pulled ahead of the other in Year 1
Combined, TRKA + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TRKA + ABBV for your $10,000?
Troika Media Group, Inc. operates as a brand consulting and marketing agency specializing in the entertainment and sports media sectors worldwide. It offers media services and analytics platform, digital marketing, data analytics and reporting, media content for events and hospitality customers, sponsorship partnerships and advertising opportunities, analytics and big data; strategic media buying and planning, design and branding, market research and insights, brand strategy, 360 brand design, advertising and sponsorship integration, brand experience and fan engagement, content creation, and sonic branding and original music services, as well as design, animation, and post production studio services. The company also provides brand fundamentals development, brand voice and personality development, marketing strategy, public relations, crisis management, and physical and digital experiential services. It serves fashion, beauty, jewelry/watches, beverage alcohol, pharmaceuticals, entertainment, consumer goods, telco, tech, sports, and automotive industries, as well as non-profit organizations. The company was formerly known as M2 nGage Group, Inc. and changed its name to Troika Media Group, Inc. in July 2017. Troika Media Group, Inc. is headquartered in Los Angeles, California.
Full TRKA Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.